ProPhase Labs, Inc.
ProPhase Labs, Inc. (PRPH) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · PRPH · as of Jun 9, 2026
Key Statistics
Explore ProPhase Labs, Inc. Data
prph stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 2 · Buy rate: 50.0%
The PRPH analyst consensus is Buy, based on ratings from 2 Wall Street analysts over the past 3 months. The average 12-month price target is $140.00, representing +139900.00% upside from the current price of $0.10.
Competitors & Peers
prph competitorsPRPH
ADAP
AEMD
ALUR
AYTU
BFRIStock Performance
Full HistoryAbout ProPhase Labs, Inc.
ProPhase Labs, Inc. founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and D…
what is prophase labs, inc. · prph stock overview · prophase labs, inc. company profile · who is prophase labs, inc. ceo · prph NASDAQ · prophase labs, inc. headquarters · prophase labs, inc. business segments
About Stock Overview & Key Data
ProPhase Labs, Inc. (PRPH) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NASDAQ since Apr 4, 1994. As of the latest trading session, PRPH stock price is $0.10, with a market capitalization of $473,701. The stock has returned -97.20% over the past 12 months and -77.78% year-to-date.
According to 2 Wall Street analysts, the consensus rating for ProPhase Labs, Inc. stock is Buy, with an average 12-month price target of $140.00. In fiscal year 2025, ProPhase Labs, Inc. reported revenue of $4.3M and net income of -$14.7M. For detailed data — including ProPhase Labs, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, ProPhase Labs, Inc. (PRPH) stock price is $0.10. The stock is traded on NASDAQ under the ticker symbol PRPH. The 52-week range is $0.07 – $6.70.